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Abstract
Previous expression quantitative trait loci (eQTL) studies have performed genetic association studies for gene expression,
but most of these studies examined lymphoblastoid cell lines from non-diseased individuals. We examined the genetics of
gene expression in a relevant disease tissue from chronic obstructive pulmonary disease (COPD) patients to identify
functional effects of known susceptibility genes and to find novel disease genes. By combining gene expression profiling on
induced sputum samples from 131 COPD cases from the ECLIPSE Study with genomewide single nucleotide polymorphism
(SNP) data, we found 4315 significant cis-eQTL SNP-probe set associations (3309 unique SNPs). The 3309 SNPs were tested
for association with COPD in a genomewide association study (GWAS) dataset, which included 2940 COPD cases and 1380
controls. Adjusting for 3309 tests (p,1.5e-5), the two SNPs which were significantly associated with COPD were located in
two separate genes in a known COPD locus on chromosome 15: CHRNA5 and IREB2. Detailed analysis of chromosome 15
demonstrated additional eQTLs for IREB2 mapping to that gene. eQTL SNPs for CHRNA5 mapped to multiple linkage
disequilibrium (LD) bins. The eQTLs for IREB2 and CHRNA5 were not in LD. Seventy-four additional eQTL SNPs were
associated with COPD at p,0.01. These were genotyped in two COPD populations, finding replicated associations with a
SNP in PSORS1C1, in the HLA-C region on chromosome 6. Integrative analysis of GWAS and gene expression data from
relevant tissue from diseased subjects has located potential functional variants in two known COPD genes and has
identified a novel COPD susceptibility locus.
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and 
the ECLIPSE Investigators
Introduction
Gene expression levels in humans are highly heritable [1,2].
Multiple published studies have examined the associations
between single nucleotide polymorphism (SNP) variation and
microarray gene expression measurements to identify expression
Quantitative Trait Loci (eQTLs ), single nucleotide polymor-
phisms (SNPs) that influence gene expression [3–5]. However,
most of the published studies have examined gene expression in
lymphoblastoid cell lines (LCL) from unphenotyped individuals
[3,4], though a recent paper has described eQTLs in peripheral
blood CD4+ lymphocytes of patients with asthma [6]. Integrative
genomic analyses can provide functional information regarding
significant SNPs found through genomewide association studies
(GWAS) or identify the key genes within a locus identified through
GWAS. For example, genome-wide expression profiling in LCL
from children with asthma [5] was used to localize ORMDL3
(ORM1-like 3 (S. cerevisiae) [MIM 610075]) as the likely gene for
childhood asthma in the multi-gene chromosome 17q21 locus
found through GWAS [7]. However, this study did not determine
whether the eQTLs identified were relevant in primary human
tissues in asthma. Integrative genomics studies can also be used to
implicate novel genes for complex traits, such as the association
betweenMMP20 (matrix metallopeptidase 20 [MIM 604629]) and
age related decline in kidney function [8].
Chronic obstructive pulmonary disease (COPD [MIM
606963]), which includes emphysema and chronic bronchitis, is
a complex disease with genetic and environmental influences [9].
COPD is a major source of morbidity and mortality in the U.S.
and worldwide [10]. Previous GWAS have identified three
susceptibility loci for COPD, including HHIP (hedgehog interact-
ing protein [MIM 606178]), FAM13A (family with sequence
similarity 13, member A [MIM 613299]), and a multi-gene locus
on chromosome 15q25 containing candidate genes CHRNA5
(cholinergic receptor, nicotinic, alpha 5 [MIM 118505]), CHRNA3
(MIM 118503), and IREB2 (iron-responsive element binding
protein 2 [MIM 147582]) [11–13]. Cough and phlegm production
is common among COPD patients, and sputum samples may
provide a non-invasive window into pathobiologic processes in the
lungs of COPD patients. Therefore, we integrated GWAS data
with microarray gene expression profiles from induced sputum
samples from well-characterized COPD subjects participating in
the Evaluation of COPD Longitudinally to Identify Predictive
Surrogate End-points (ECLIPSE) Study [14]. We addressed two
hypotheses: (1) eQTL analysis will improve understanding of
previously known COPD susceptibility loci, such as chromosome
15q25; and (2) eQTL SNPs can be used to identify novel COPD
susceptibility genes. Limiting the search to functional eQTL SNPs
can reduce the multiple testing burden found in traditional
GWAS. Although eQTL studies have now been performed in
several human tissues besides blood, our study represents one of
the first integrative genomics analyses performed in affected
patients in order to gain insights into a common disease.
Methods
Ethics Statement
Study subjects provided written informed consent, and all
studies were approved by the Institutional Review Boards at
Partners Healthcare and all participating centers.
ECLIPSE Study
ECLIPSE was a three year observational study conducted at 46
centers in 12 countries [14]. ECLIPSE recruited 2083 COPD
subjects ages 40–75 with a smoking history of at least 10 pack-
years (cigarettes smoked per day multiplied by years smoked,
divided by 20 to convert to packs), 332 control smokers with at
least 10 pack-years smoking history and normal lung function, and
237 non-smoking controls [15]. COPD was defined by GOLD
stage 2 or greater (FEV1/FVC,0.7 with FEV1,80% predicted)
[10]. Genome-wide SNP genotyping was performed on all
ECLIPSE subjects using the Illumina HumanHap550 BeadChip.
GWAS analysis included 1736 cases COPD cases and 175 controls
[11]. Sputum induction was performed on a subset of COPD cases
at 14 sites, using a standard protocol [16]. RNA was extracted
from sputum cell pellets using TRIzol and amplified with the
Nugen Ovation RNA Amplification kit. Gene expression profiling
was performed on RNA extracted from sputum samples of 145
COPD cases (all ex-smokers) using the Affymetrix Human U133
Plus2 array [17]. MIAME-compliant array data are available in
the Gene Expression Omnibus database (http://www.ncbi.nlm.
nih.gov/geo), accession GSE22148. Only Caucasian subjects were
included in this analysis.
Other GWAS Populations
Subjects from two additional COPD case-control studies were
merged with the ECLIPSE subjects in the combined GWAS
analysis and the GWAS meta-analysis [11]. COPD cases and
control smokers were Caucasians recruited in Bergen, Norway
[18,19]. Cases were defined by GOLD stage 2 or greater COPD;
smoking controls had normal lung function. Both cases and
controls had smoking history of at least 2.5 pack-years. GWAS
included 838 cases and 791 controls, genotyped using the Illumina
HumanHap550 BeadChip [12].
The National Emphysema Treatment Trial (NETT) cases have
FEV1#45% predicted and emphysema on chest CT scan [20,21].
Thus, NETT cases have COPD severity of GOLD Stage 3 or
greater. All NETT Genetics Ancillary Study subjects are former
smokers; only white subjects are included in this analysis. The
Normative Aging Study (NAS) is a cohort study of initially healthy
men followed by the Boston VA [22]. To define a control group
for comparison to NETT cases, we selected Caucasian subjects
meeting the following criteria: FEV1.80% predicted, FEV1/
FVC.90% predicted, at least 10 pack-years of smoking, and an
adequate DNA sample [23]. Genomewide SNP genotyping has
been performed in the NETT-NAS study (366 cases, 414 controls)
using the Illumina 610-Quad BeadChip [11].
Replication Populations
The International COPD Genetics Network (ICGN) was a
family-based study of COPD at ten centers in North America and
Europe [18,24]. Probands were ages 45–65 with post-bronchodi-
lator FEV1,60% predicted, FEV1/VC,90% predicted, a
smoking history of at least 5 pack-years, and at least one sibling
with $5 pack-year smoking history. Genotyping was performed
on Caucasian subjects only (Table 1).
The Genetic Epidemiology of COPD Study (COPDGene)
enrolled COPD cases and control smokers at 21 clinical centers
throughout the United States [25]. Subjects are 45–80 years old
and have a smoking history of at least 10 pack-years. This analysis
included the first 994 non-Hispanic white case and control subjects
enrolled in COPDGene (Table 1). In these samples, a set of 75
ancestry informative markers has been previously genotyped and
did not show evidence of population stratification [11].
SNP genotyping in ICGN and COPDGene SNPs was done
using the iPLEX Gold assay on the Sequenom (San Diego, CA)
MassARRAY system [26] or the TaqMan 59 exonuclease assay
(Applied Biosystems, Foster City, CA) [27].
Sputum Integrative Genomics in COPD
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Statistical Analysis
A total of 145 COPD subjects had sputum samples with gene
expression data available; two arrays failed quality control. Of the
remaining 143 subjects, 131 had corresponding genomewide SNP
data and phenotype data. The Affymetrix HG-U133 Plus 2 array
contains 54,675 probe sets. After filtering out 17,420 probe sets
which were not annotated with a specific gene symbol in the
hgu133plus2.db R/Bioconductor database or which mapped to
the X or Y chromosomes, 37,255 probe sets remained. Microarray
preprocessing used the robust multiarray average method and
quantile normalization [28], implemented in Bioconductor. QC of
microarrays was performed using the Bioconductor package
affyQCReport; QC results are available in the Data S1 and in
Figure S1. QC of genomewide SNP data in ECLIPSE has been
reported [11]. SNPs with minor allele frequency ,0.05 in the 131
ECLIPSE cases were additionally excluded.
In the integrative analysis, each expression probe set was mapped
to its corresponding gene and all genotyped SNPs were identified
within 50 kb of the transcription start site (TSS). General linear
models were used to detect cis-acting associations between probe set
expression levels and SNP genotypes, adjusted for age, gender, and
the first six genetic ancestry principal components derived from the
genotype data on all ECLIPSE COPD cases [29]. False discovery
rate adjusted p-value,0.05 defined statistical significance. eQTL
analysis utilized the GGTools Bioconductor package [30].
Each significant cis-eQTL SNP was then tested for association
with COPD in the combined GWAS dataset from ECLIPSE,
Norway, and NETT-NAS [11]. The published combined GWAS
analysis was a mega-analysis of individual-level genotype data,
using logistic regression, adjusted for age, pack-years of smoking
and principal components for genetic ancestry. In the published
meta-analysis, stratified logistic regression was performed within
each case-control study and results were combined using Z-scores
for weighting by the inverse variance. SNPs associated with
COPD at p,0.01 in either the combined GWAS analysis (mega-
analysis) or the GWAS meta-analysis were genotyped for
replication in ICGN and COPDGene. In the COPDGene study,
case-control data were analyzed with linear regression models,
adjusted for age, sex, and pack-years of smoking, using PLINK
version 1.0.7 [31]. Family-based ICGN data were analyzed in
PBAT version 3.6.1, adjusted for age, sex, and pack-years of
smoking [32].
We also tested for eQTL SNPs influencing the expression of
genes in previously identified COPD loci. On chromosome 15q25,
we defined a region starting 50 kb centromeric from IREB2
extending 50 kb telomeric from CHRNB4 (approx. 300 kb total)
and tested all genotyped SNPs within this region for association
with expression levels of probe sets for six genes: IREB2, AGPHD1,
PSMA4, CHRNA5, CHRNA3, and CHRNB4. For the other two
COPD loci, we expanded the cis-eQTL analysis to all SNPs with
200 kb of the TSS of the genes HHIP and FAM13A.
Results
Sputum eQTL Analysis
Characteristics of the 131 ECLIPSE COPD subjects in the
eQTL analysis are shown in Table 1. On average, COPD subjects
had a heavy smoking history and severely impaired lung function,
similar to the full set of ECLIPSE GWAS cases [11]. The data
analysis is outlined in Figure 1. Combining the gene expression
data with genomewide SNP data and limiting analysis to potential
cis-acting SNPs (within 50 kb of TSS) yielded 562,787 SNP-probe
set association tests. Of these, 4315 SNP-probe set associations
were significant at FDR-adjusted p,0.05 (corresponding to
unadjusted p= 3.8e-4), representing 3309 unique SNPs and
1399 unique probe sets, covering 1086 genes (Table S1).
The top eQTL was for SNP rs104664 within the gene
FAM118A (family with sequence similarity 118, member A). This
SNP was found to be highly associated with FAM118A expression
(Affymetrix Human 1.0 ST Exon array) in human osteoblasts [33],
suggesting cross-tissue generalizability of this eQTL association.
Other significant eQTL associations observed in sputum included
CHURC1 (churchill domain containing 1 [MIM 608577]), HLA-
DQB1 (major histocompatibility complex, class II, DQ beta 1
[MIM 604305]) and HLA-DQA1 (MIM 146880), all of which were
previously been found in other tissues, such as LCL [4,34] and
brain [35], according to a search of the GTEx (Genotype-Tissue
Expression) eQTL Browser (http://www.ncbi.nlm.nih.gov/gtex,
accessed 11/30/2010).
Sputum eQTLs associated with COPD
We queried the 3309 significant cis-eQTL SNPs in the combined
GWAS dataset including ECLIPSE, Norway, and NETT-NAS
subjects [11]. Using a strict Bonferroni correction, there were two
Table 1. Characteristics of Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study subjects
in the integrative genomics analysis as well as subjects from the International COPD Genetics Network (ICGN) and the Genetic
Epidemiology of COPD study (COPDGene) included in follow-up analyses.
ECLIPSE ICGN COPDGene
Cases Probands Relatives Cases Controls
N 131 983 1876 496 498
Male sex 87 (66.4%) 580 (59.0%) 970 (51.7%) 244 (49.2%) 251 (50.4%)
Age 64.9 (65.5) 58.4 (65.4) 57.9 (69.5) 64.7 (68.1) 60.3 (68.6)
Pack-years of smoking 46.8 (628.3) 52.7 (629.5) 39.2 (625.3) 54.8 (626.8) 38.8 (621.0)
Current smoker 0 320 (32.6%) 956 (51.0%) 149 (30.0%) 168 (33.7%)
Post-bronchodilator FEV1, % predicted 49.3 (615.3) 35.5 (613.1) 83.3 (626.0) 48.8 (618.4) 98.0 (611.3)
Post-bronchodilator FEV1/FVC 0.43 (60.12) 0.37 (60.12) 0.64 (60.14) 0.48 (60.13) 0.78 (60.05)
Values are presented as mean (6SD) or N (%).
FEV1 = forced expiratory volume in 1 second.
FVC = forced vital capacity.
doi:10.1371/journal.pone.0024395.t001
Sputum Integrative Genomics in COPD
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cis-eQTL SNPs significantly associated with COPD at p,0.05/
3309=1.5e-5 (Table 2). These two SNPs on chromosome 15q25
are located in CHRNA5 and IREB2, genes with known COPD
associations.[12,36] At a nominal threshold of p,0.01, there were
64 cis-eQTL SNPs associated with COPD (Table S2). There were
56 eQTL SNPs associated with COPD at p,0.01 in the meta-
analysis of the ECLIPSE, Norway, NETT-NAS GWAS studies
(Table S3), as opposed to the combined analysis of individual-level
genotype data. Merging the 64 SNPs from the combined GWAS
analysis and the 56 SNPs from the GWAS meta-analysis left 76
unique SNPs, which were brought to replication analysis.
Replication Studies
Characteristics of the ICGN and COPDGene subjects in the
replication analysis are reported in Table 1. The two SNPs in
Table 2 were analyzed in previous reports [12,36] and were not
retested. Of the remaining 74 SNPs, 69 were successfully
genotyped in ICGN and COPDGene. Screening in the larger
ICGN study found 8 SNPs with p,0.1 (Table 3). Of these, only
one had p,0.1 in COPDGene. SNP rs1265098 was significantly
associated with COPD in ICGN and had a trend for significance
in COPDGene. The effect direction for rs1265098 was consistent
in ICGN, COPDGene, and the combined GWAS; the minor
allele was associated with increased COPD risk in all three studies.
SNP rs1265098 maps to the gene PSORS1C1 (psoriasis suscepti-
bility 1 candidate 1 [MIM 613525]) on chromosome 6, yet is
associated with transcript levels of the neighboring gene
PSORS1C3 (p = 8.2e-05, FDR-adjusted p= 0.016) (Figure 2).
Sputum eQTLs in COPD Candidate Loci
Previous GWAS have identified three loci associated with
COPD susceptibility: HHIP on chromosome 4q31 [12,13],
FAM13A on chromosome 4q22 [11], and a region on chromosome
15q25 encompassing candidate genes CHRNA5, CHRNA3 and
IREB2, among others [12,36]. On chromosome 15q25, cis-eQTL
associations for IREB2 mapped to that gene (Figure 3a). Genetic
regulation of CHRNA5 was more complex. Previous studies have
demonstrated cis-acting effects of multiple SNPs on CHRNA5
expression. Saccone et al. defined 4 LD bins surrounding CHRNA5
with varying associations with cigarette smoking, lung cancer, and
COPD [37]. Bins 1–3 were represented in our dataset, tagged by
SNPs rs1051730, rs938682, and rs6495306, respectively (Table 4).
SNPs in bins 1 and 3 were associated with CHRNA5 expression in
sputum (Figure 2), as has been demonstrated in brain [38] and
lung tissue [39]. SNPs in bin 2 were not eQTLs for CHRNA5. We
added additional SNPs to these bins, based on strong LD with tag
SNPs in the larger ECLIPSE GWAS dataset. We also identified 3
sets of SNPs (3a, b, c in Table 4) with cis-eQTL associations for
CHRNA5 and moderate LD with SNPs in bin 3 (r2 0.57–0.76).
SNPs in bins 1 and 2, but not bin 3, showed evidence of
association with COPD in the combined GWAS dataset, though
they were not genomewide significant (bin 1: rs1051730, p = 2.8e-
6; bin 2: rs938682, p = 5.6e-5; bin 3: rs6495306, p = 0.2). These
results suggest that the COPD-associated SNP rs1051730 (bin 1)
may influence phenotype by its effect on gene expression, while
COPD-associated SNPs in bin 2 (tagged by rs938682) may exert
their effect through other mechanisms. SNPs in bin 3, although
eQTLs, were not associated with COPD risk.
SNPs in IREB2 were both cis-eQTLs for that gene (Table 4,
Figure 2) and were associated with COPD in the combined
GWAS (rs13180, p = 5.0e-7). Even though some of the significant
eQTL SNPs for CHRNA5 mapped to IREB2 (bin 3a), SNPs in all 3
bins were not in LD with the IREB2 eQTL SNPs (Figure 3b). No
SNPs were significantly associated with AGPHD1, PSMA4, or
CHRNB4 gene expression. For the other two COPD GWAS loci,
HHIP and FAM13A, we found no significant cis-eQTL SNPs
Figure 1. Overview of integrative genomics data analysis.
*Combined genomewide association study (GWAS) = Evaluation of
COPD Longitudinally to Identify Predictive Surrogate End-points
(ECLIPSE), Bergen Norway, and National Emphysema Treatment Trial
(NETT)-Normative Aging Study (NAS) [11]. COPD= chronic obstructive
pulmonary disease. eQTL = expression quantitative trait locus.
FDR= false discovery rate. ICGN= International COPD Genetics Network.
SNP= single nucleotide polymorphism.
doi:10.1371/journal.pone.0024395.g001
Table 2. Sputum cis-eQTL SNPs significantly associated with COPD in the combined COPD GWAS.
Chrom location SNP Affy probe Gene eQTL pvalue
FDR-adjusted
pvalue
GWAS COPD
ORa
GWAS COPD
pvaluea
GWAS pvalue
(adjusted)b
15 76532762 rs2656069 1555476_at IREB2 0.00030 0.042 0.75 6.8E-06 0.023
15 76681394 rs1051730 206533_at CHRNA5 0.00015 0.026 1.29 2.8E-06 0.0093
aCombined COPD genomewide association study (GWAS) according to Cho et al. [11].
bBonferroni correction for 3309 sputum expression quantitative trait locus (eQTL) single nucleotide polymorphisms (SNPs) tested.
doi:10.1371/journal.pone.0024395.t002
Sputum Integrative Genomics in COPD
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within 50 kb, so we expanded the assessment of cis-eQTLs to all
SNPs within 200 kb of the TSS of each gene. There were no
significant cis-eQTLs within 200 kb of either HHIP or FAM13A.
Discussion
In a cohort of well-characterized COPD subjects, we integrated
genomewide SNP and gene expression data derived from induced
sputum, a biologically-relevant tissue in COPD, to identify a set of
eQTL SNPs affecting gene expression levels. The SNPs were then
tested for association with the clinical phenotype of COPD; gene
expression was not tested for association with disease status in this
set of COPD cases only. Using the eQTL results, we implicated
two distinct COPD susceptibility genes in a previously identified
region of chromosome 15q25. Additionally, we provide evidence
for a potential novel COPD susceptibility locus in the HLA region
on chromosome 6.
The initial GWAS in COPD found significant associations on
chromosome 15q25, with SNPs in the genes CHRNA3 and
CHRNA5, encoding two subunits of the nicotinic acetylcholine
receptor [12]. This region has also been associated with lung
cancer, peripheral arterial disease, and smoking behavior [37,40–
43], so it is not clear whether these genes have a direct effect on
COPD susceptibility, or their effects are at least partially
influenced through cigarette smoking, the major environmental
risk factor for COPD [44,45]. In terms of genetic regulation of
expression of the chromosome 15q25 genes, we found similar
eQTL associations with CHRNA5 expression in induced sputum as
has been found in brain [38] and lung tissue [39]. We found
additional sputum eQTL SNPs for CHRNA5 in moderate LD with
previously defined eQTLs. The previous papers on brain and lung
tissue gene expression did not report testing IREB2, a gene
previously associated with COPD [11,36]. The specific IREB2
SNPs associated in GWAS (rs13180) [11] and in a candidate gene
analysis of differentially expressed genes (rs2656069) [36] were in
only moderate LD (r2 = 0.44) with each other, implying indepen-
dent effects on IREB2 expression. The IREB2 and CHRNA5 eQTL
SNPs were not in LD with each other, suggesting the presence of
at least two COPD susceptibility genes on chromosome 15q25.
Previous studies have similarly used eQTL analyses to add
functional information about genes identified through GWAS,
including studies of asthma [7], celiac disease [46], and Crohn’s
disease [47]. However, these prior studies have examined gene
expression in blood cells, and not primary disease tissues.
However, we did not finding significant cis-eQTL SNPs for two
other known COPD loci, HHIP and FAM13A. The associated
SNPs found through GWAS may exert their effects on phenotype
via other mechanisms besides influencing gene expression.
Alternatively, the GWAS SNPs may actually be eQTLs acting
in other tissues besides sputum, such as alveolar or bronchial
epithelial cells, which were not assessed in our study.
Besides improving understanding of the COPD susceptibility
locus on chromosome 15q25, we identified a potential novel
COPD locus on chromosome 6. The SNP maps to gene
PSORS1C1, but it is associated with expression levels of the
neighboring gene PSORS1C3. Variants in PSORS1C3 have been
reported to be associated with psoriasis [48], an immune-mediated
skin disease. PSORS1C3 is located in the major histocompatability
(MHC) region, and subsequent papers have found that the
associations with psoriasis may be due to variants in HLA-C (MIM
142840) [49,50]. Interestingly, one study has reported an
epidemiologic association between psoriasis and COPD [51],
and cigarette smoking is a risk factor for psoriasis as well [52].
Although there are no reports of HLA-C associations with COPD,
alleles of other MHC class I genes, HLA-A and HLA-B, have been
associated with COPD [53,54]. The locus encompassing
PSORS1C1/3 and HLA-C will require additional replication studies
and functional validation to confirm its role in COPD suscepti-
bility.
Prior studies have also used eQTL analyses to identify novel
genes for complex traits, including age related decline in kidney
function [8] and body mass index [55]. In contrast to our study,
these papers first found gene transcripts correlated with the
phenotype, then tested SNPs in/near these genes for association
with expression levels. We performed the cis-eQTL analysis as the
initial step, then tested the eQTL SNPs for phenotype association.
This limits multiple testing compared to a GWAS, enriching for
eQTL SNPs which may be more likely to be associated with
disease [56].
This study has several limitations. The sample size of 131
subjects, though adequate for gene expression analyses, may be
underpowered to detect all potential eQTL associations.
Therefore, we limited the cis-acting analysis to SNPs within
50 kb from the gene, to limit the multiple testing burden. Based
Table 3. Genetic association analysis of sputum expression quantitative trait locus (eQTL) single nucleotide polymorphisms (SNPs)
with COPD susceptibility.
SNP Chrom BP Gene
Effect on COPD
risk in ICGN ICGN pvalue COPDGene OR
COPDGene
pvalue GWAS ORa
GWAS
pvaluea
rs1999261 6 6515106 INTERGENIC Increase 0.042 0.94 0.53 1.15 0.0080
rs1265098 6 31214156 PSORS1C1 Increase 0.024 1.20 0.098 1.18 0.0065
rs4750277 10 12954527 INTERGENIC Increase 0.0062 0.97 0.80 0.83 0.0097
rs1025607 12 94884637 AMDHD1 Increase 0.011 1.12 0.26 a a
rs2347279 18 2528545 METTL4 Decrease 0.097 1.01 0.91 0.83 0.0025
rs1878553 18 2560155 NDC80 Decrease 0.030 1.03 0.83 0.83 0.0028
rs4803481 19 46758396 INTERGENIC Decrease 0.055 0.97 0.81 a a
rs2302188 19 46777713 CEACAM21 Decrease 0.090 0.97 0.77 0.85 0.0075
SNPs with p-value,0.1 in the International COPD Genetics Network (ICGN) are shown.
aOdds Ratio and p-value from combined genomewide association study (GWAS) analysis [11] are shown, except as noted:
rs1025607 p= 0.0089 in GWAS meta-analysis.
rs4803481 p= 0.0043 in GWAS meta-analysis.
doi:10.1371/journal.pone.0024395.t003
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Figure 2. Boxplots of sputum gene expression levels stratified by genotype in 131 Evaluation of COPD Longitudinally to Identify
Predictive Surrogate End-points (ECLIPSE) subjects with chronic obstructive pulmonary disease. a) rs1265098 - PSORS1C3 (238997_at),
p = 8.2e-5. b) rs13180 - IREB2 (1555476_at), p = 6.7e-9. c) rs1051730 - CHRNA5 (206533_at), p = 2.2e-4; LD bin 1 (see Table 4). d) rs6495306 - CHRNA5
(206533_at), p = 9.9e-6; LD bin 3 (see Table 4).
doi:10.1371/journal.pone.0024395.g002
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on RNA sequencing data, Pickrell et al. estimate that 90% of
eQTL SNPs are within 15 kb of a gene [57]. Previous papers
have used a 50 kb limit to define cis-acting eQTLs [6]. Using this
method, we were able to replicate published eQTL associations
from other tissues and were able to identify a set of significant
eQTL SNPs to carry forward for COPD association studies.
However, our method would be unable to detect cis-eQTLs
located .50 kb from the TSS, such as a SNP in an upstream
enhancer or in the 39 UTR of a large gene. Due to the sample
size, we limited our investigation to cis-acting eQTL SNPs, as a
full search for trans-acting regulatory SNPs greatly increases the
number of tests performed. The literature suggests that sample
sizes under 200 subjects may be inadequate to find true trans-
eQTLs [58].
Figure 3. Detailed analysis of the chromosome 15q25 chronic obstructive pulmonary disease (COPD) locus. a) Association between
single nucleotide polymorphisms (SNPs) in the chromosome 15q25 COPD locus and expression levels of IREB2 (1555476_at), CHRNA5 (206533_at) and
CHRNA3 (211587_x_at) in sputum samples from 131 Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) subjects.
SNP rs numbers are listed in Table 4. b) Linkage disequilibrium r2 values between SNPs in the chromosome 15q25 COPD locus (listed in Table 4) in 131
ECLIPSE subjects.
doi:10.1371/journal.pone.0024395.g003
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Table 4. Single nucleotide polymorphism (SNP) associations with expression of IREB2 (1555476_at) and CHRNA5 (206533_at) in
induced sputum samples from COPD subjects.
SNP Position IREB2 eQTL pvalue CHRNA5 eQTL pvalue LD bin r2 with locus tag r2 with rs13180
rs4243082 78682076 0.88 0.89
rs11635084 78686823 0.066 0.82
rs2869040 78688834 0.26 0.68
rs6495296 78696492 0.32 0.71
rs4887052 78703631 0.26 0.88
rs7171749 78708715 0.41 0.44
rs12913946 78709937 0.30 0.72
rs7183034 78710766 0.16 0.66
rs4887053 78712699 0.0012 0.11
rs1394371 78724469 0.0028 0.031
rs12903150 78724645 0.014 0.0014
rs12899131 78726885 0.71 2.8E-05 3a 0.57 ,0.01
rs10519198 78742754 0.73 3.3E-05 3a 0.57 ,0.01
rs2656069 78745707 4.0E-04 0.11 IREB2 0.44
rs13180 78789488 6.7E-09 0.74 IREB2
rs3743079 78791061 3.9E-04 0.063 IREB2 0.36
rs1062980 78792527 7.7E-09 0.78 IREB2 0.99
rs8034191 78806023 0.010 3.8E-04 1 0.90
rs3885951 78825917 0.025 0.20
rs2036534 78826948 0.0015 0.043 2 0.79
rs12915366 78831753 0.83 3.7E-07 3 0.80
rs2292117 78834689 0.80 6.4E-07 3 0.82
rs6495306 78865893 0.79 9.9E-06 3 ,0.01
rs680244 78871288 0.79 9.9E-06 3 0.99
rs621849 78872861 0.79 9.9E-06 3 0.99
rs578776 78888400 0.016 0.70 2 0.72
rs12910984 78891627 0.0061 0.45 2 0.99
rs1051730 78894339 0.016 2.2E-04 1 0.19
rs3743077 78894896 0.93 6.7E-05 3 0.98
rs938682 78896547 0.0061 0.45 2 0.26
rs12914385 78898723 0.014 8.0E-04 1 0.81
rs8042374 78908032 0.0064 0.53 2 0.98
rs3743075 78909452 0.76 2.0E-04 3b 0.76 0.01
rs6495309 78915245 0.088 0.64 2 0.90
rs1948 78917399 0.16 4.2E-04 3c 0.60 0.03
rs11636753 78928946 0.91 0.0023
rs12441998 78929372 0.14 0.85
rs1316971 78930510 0.083 0.89
rs12594247 78946633 0.63 0.62
rs17487514 78953785 0.10 0.068
rs1996371 78956806 0.025 0.025
rs6495314 78960529 0.025 0.025
rs922691 78963994 0.14 0.0060
rs8032156 78964498 0.51 0.66
rs8038920 78974545 0.059 0.011
rs4887077 78978364 0.049 0.029
rs11638372 78983559 0.049 0.029
Linkage disequilibrium (LD) bins for CHRNA5 associations are defined as in Saccone et al. [37]. SNPs tags for LD bins are shown in bold. Additional SNPs added to bins
based on LD in ECLIPSE genomewide association study dataset are shown in italics.
doi:10.1371/journal.pone.0024395.t004
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Several groups have compared eQTLs in different tissues from
the same individual, finding both overlapping and tissue-specific
eQTLs [59–61]. Multiple tissues are known to be important in
COPD biology, including large and small airways, lung paren-
chyma and immune cells. By only surveying sputum, we may have
missed significant eQTLs for COPD genes that are expressed in
other tissues. Multiple cell types may be present in sputum, yet
neutrophils have been shown to be the predominant cell type in
the sputum samples from COPD subjects in ECLIPSE [16].
Despite these limitations, sputum is a clinically important tissue in
COPD and is more accessible for genomic and biomarkers studies
than lung tissue. Studying diseased individuals may be advanta-
geous to identify eQTL SNPs for potential disease genes, which
may only be expressed, or may be expressed at higher levels, in
patients compared to healthy controls.
In conclusion, we combined genomewide SNP genotyping with
genomewide expression profiling from a relevant tissue in well-
characterized subjects with a common chronic disease. Using this
strategy, we were able to gain insights into the functional role of
SNPs previously associated through GWAS, as well as identify a
potential novel disease susceptibility gene which would have been
missed using standard GWAS analysis. Previous eQTL studies
have provided important information about genetic control of
human gene expression. Integrative genomics studies in relevant
tissue from well-phenotyped individuals, as we have performed,
will be required to apply this knowledge to human disease.
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